Claims for Patent: 5,260,074

Summary for Patent: 5,260,074

Title:	Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
Abstract:	Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, impaired liver function, cystic fibrosis, regulating the absorption of dietary cholesterol, and for dissolving gallstones by administering the compositions to a mammal in need of such treatment.
Inventor(s):	Sipos; Tibor (Lebanon, NJ)
Assignee:	Digestive Care Inc. (Lebanon, NJ)
Application Number:	07/901,734
Patent Claims:	1. A process for preparing a digestive enzyme and bile salt composition for the treatment of digestive enzyme and bile salt deficiencies in mammals comprising the steps of: a) blending in dry, powdery form (i) about 71 to about 90% w/w of an enzyme selected from the group consisting of pancreatic proteases, lipases, nucleases and amylases; (ii) about 1.0 to about 61% w/w of a salt of ursodeoxycholic acid selected from the group consisting of sodium, potassium, ammonium, tromethamine, ethanolamine, diethanolamine and triethanolamine; (iii) about 0.8 to about 5.0% w/w of a buffering agent consisting of anhydrous sodium carbonate, sodium bicarbonate, potassium carbonate or potassium bicarbonate in combination with about 0.8 to about 1.5% w/w of tromethamine, diethanolamine or triethanolamine; (iv) about 0.3 to about 19% w/w of an adhesive polymer selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone, cellulose acetate, phthalate and methyl cellulose; (v) about 0.9 to about 16% w/w of a disintegrant selected from the group consisting of starch, modified starches, microcrystalline cellulose and propylene glycol alginate; b) wetting said blended ingredients with a liquid to cause the blend to stick together, wherein said liquid is selected from the group consisting of (i) 1-25% w/w ethanol, 75-99% w/w 2-propanol, and 0.2-2% w/w water, (ii) 98-99% w/w 2-propanol and 0.2-2% w/w water, and (iii) 1-25% w/w methanol, 0.2-2% w/w water, 75-98% w/w 2-propanol and 1-5% w/w ethylacetate; c) granulating or extruding the blend through a 10 or 18 mesh S/S screen; d) converting the granules to a uniform diameter particle size; e) compacting the uniform particles into spherical particles; f) drying the spherical particles; g) coating the particles with a gastric acid-resistant polymer that disintegrates under neutral or basic conditions; and h) drying the polymer-coated spherical particles. 2. The process of claim 1 wherein said digestive enzyme is selected from the group consisting of Pancreatin, Pancrelipase, Trypsin, Chymotrypsin, Chymotrypsin B, Pancreatopeptidase, Carboxypeptidase A, Carboxypeptidase B, Glycerol Ester Hydrolase, Phospholipase A2, Sterol Ester Hydrolase, Ribonuclease, Deoxyribonuclease, .alpha.-Amylase, Papain, Chymopapain, Bromelain, Ficin, .beta.-Amylase, Cellulase and .beta.-Galactosidase. 3. The process of claim 1 wherein said composition is in the form of microspheres having a mesh size of about 10 to 80. 4. The process of claim 1 wherein said liquid for wetting the blended ingredient comprises from about 0.2% to about 2.0% water. 5. The process of claim 4 wherein said water content is from 0.2 to 1.5%. 6. The process of claim 5 wherein said water content is from 0.2 to 1.0%. 7. The process of claim 1 wherein the particle size range of said seeds is from about 20 to about 60 mesh. 8. The process of claim 1 for preparing a digestive enzyme and bile salt composition for the treatment of digestive enzyme and bile salt deficiencies in mammals comprising the steps of: a) preparing starting seeds of the bile salt comprising blending the powdery bile salt with the disintegrant and the buffering agent; b) spraying said blend with a solution of the adhesive polymer until the blend agglomerates; c) granulating or extruding the agglomerate through a 10 or 18 mesh S/S screen; d) converting the granules to a uniform diameter particle size of 40 to 60 mesh; e) compacting the uniform diameter particles into spherical particles; f) drying the spherical particles to obtain the starting seeds; g) tumbling the starting seeds in a rotating coating pan, wetting the starting seeds with a solution of the adhesive polymer and dusting the starting seeds while tumbling in the rotating coating pan with the powdery buffered bile salt, enzyme, and disintegrant composition to obtain particles in the 10 to 20 mesh size range; h) coating the 10 to 20 mesh size particles with a gastric acid-resistant polymer that dissolves under neutral or basic conditions; and i) drying the polymer-coated particles. 9. The process of claim 8 wherein said starting seed is selected from the group consisting of (i) sodium or potassium salts or ursodeoxycholic acid, (ii) ethyl or propyl esters of ursodeoxycholic acid, (iii) sodium or potassium salts of glycyl and tauroursodeoxycholate and (iv) sodium or potassium salts of N-methyl glycyl and N-methyl tauroursodeoxycholate. 10. A method for treating digestive enzyme and bile salt deficiencies in mammals comprising orally administering to said mammals a therapeutically effective amount of the composition of claim 1.

Details for Patent 5,260,074

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	November 10, 1982	5,260,074	2040-03-30
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	August 21, 1984	5,260,074	2040-03-30
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	December 09, 1996	5,260,074	2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	April 30, 2009	5,260,074	2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	June 10, 2011	5,260,074	2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	March 14, 2013	5,260,074	2040-03-30

International Patent Family for US Patent 5,260,074

Country	Patent Number	Estimated Expiration
United States of America	5578304
United States of America	5460812
United States of America	5324514
European Patent Office	0576938
Canada	2096002
Australia	666015